T2 Biosystems (TTOO) announced that its multi-year capital equipment supplier agreement with Vizient has been extended through March 31, 2026. The products covered under the contract with Vizient include the T2Dx Instrument, the T2Bacteria Panel and the T2Candida Panel, which detect sepsis-causing bacterial and fungal pathogens directly from whole blood. Through the extended contract, Vizient members will continue to have access to broader exposure and contracted pricing for the T2Dx Instrument, the T2Bacteria Panel and the T2Candida Panel, the only FDA-cleared products able to detect sepsis-causing pathogens directly from whole blood.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TTOO:
- T2 Biosystems Advances Sepsis Detection Technology Licensing
- T2 Biosystems announces plans to license technology to expand its leadership
- T2 Biosystems Reports Increased Losses and Cash Crunch
- TTOO Earnings this Week: How Will it Perform?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
